# Phase 2/3 Study of ALK-001 in Geographic Atrophy

> **NCT03845582** · PHASE2,PHASE3 · COMPLETED · sponsor: **Alkeus Pharmaceuticals, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Geographic Atrophy
- Age Related Macular Degeneration
- AMD
- Atrophy, Geographic

## Interventions

- **DRUG:** ALK-001 oral capsule
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03845582
- **Lead sponsor:** Alkeus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-07
- **Primary completion:** 2023-07-25
- **Final completion:** 2024-06-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2025-11-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03845582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03845582, "Phase 2/3 Study of ALK-001 in Geographic Atrophy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03845582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*